The roles of tertiary lymphoid structures in genitourinary cancers: molecular mechanisms, therapeutic strategies, and clinical applications

被引:0
作者
Yang, Jie [1 ]
Xiong, Xingyu [1 ]
Zheng, Weitao [1 ]
Xu, Hang [1 ]
Liao, Xinyang [1 ]
Wei, Qiang [1 ]
Yang, Lu [1 ]
机构
[1] Sichuan Univ, West China Hosp, Inst Urol, Dept Urol, Chengdu, Sichuan, Peoples R China
基金
中国国家自然科学基金;
关键词
antitumor immunity; genitourinary cancer; immune checkpoint blockade; tertiary lymphoid structures; tumor immune microenvironment; RESISTANT PROSTATE-CANCER; RENAL-CELL CARCINOMA; PHASE-III TRIAL; B-CELLS; T-CELLS; UROTHELIAL CARCINOMA; PROGNOSTIC RELEVANCE; CHRONIC INFLAMMATION; IMMUNE CONTEXTURE; PLASMA-CELLS;
D O I
10.1097/JS9.0000000000001939
中图分类号
R61 [外科手术学];
学科分类号
摘要
The presence of tertiary lymphoid structures (TLSs) associated with distinct treatment efficacy and clinical prognosis has been identified in various cancer types. However, the mechanistic roles and clinical implications of TLSs in genitourinary (GU) cancers remain incompletely explored. Despite their potential role as predictive markers described in numerous studies, it is essential to comprehensively evaluate the characteristics of TLSs, including drivers of formation, structural foundation, cellular compositions, maturation stages, molecular features, and specific functionality to maximize their positive impacts on tumor-specific immunity. The unique contributions of these structures to cancer progression and biology have fueled interest in these structures as mediators of antitumor immunity. Emerging data are trying to explore the effects of therapeutic interventions targeting TLSs. Therefore, a better understanding of the molecular and phenotypic heterogeneity of TLSs may facilitate the development of TLSs-targeting therapeutic strategies to obtain optimal clinical benefits for GU cancers in the setting of immunotherapy. In this review, the authors focus on the phenotypic and functional heterogeneity of TLSs in cancer progression, current therapeutic interventions targeting TLSs and the clinical implications and therapeutic potential of TLSs in GU cancers.
引用
收藏
页码:5007 / 5021
页数:15
相关论文
共 164 条
  • [11] Bergomas Francesca, 2011, Cancers (Basel), V4, P1, DOI 10.3390/cancers4010001
  • [12] Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
    Bi, Kevin
    He, Meng Xiao
    Bakouny, Ziad
    Kanodia, Abhay
    Napolitano, Sara
    Wu, Jingyi
    Grimaldi, Grace
    Braun, David A.
    Cuoco, Michael S.
    Mayorga, Angie
    DelloStritto, Laura
    Bouchard, Gabrielle
    Steinharter, John
    Tewari, Alok K.
    Vokes, Natalie, I
    Shannon, Erin
    Sun, Maxine
    Park, Jihye
    Chang, Steven L.
    McGregor, Bradley A.
    Haq, Rizwan
    Denize, Thomas
    Signoretti, Sabina
    Guerriero, Jennifer L.
    Vigneau, Sebastien
    Rozenblatt-Rosen, Orit
    Rotem, Asaf
    Regev, Aviv
    Choueiri, Toni K.
    Van Allen, Eliezer M.
    [J]. CANCER CELL, 2021, 39 (05) : 649 - +
  • [13] Stromal Cells in Chronic Inflammation and Tertiary Lymphoid Organ Formation
    Buckley, Christopher D.
    Barone, Francesca
    Nayar, Saba
    Benezech, Cecile
    Caamano, Jorge
    [J]. ANNUAL REVIEW OF IMMUNOLOGY VOL 33, 2015, 33 : 715 - 745
  • [14] Epidemiology of Renal Cell Carcinoma: 2022 Update
    Bukavina, Laura
    Bensalah, Karim
    Bray, Freddie
    Carlo, Maria
    Challacombe, Ben
    Karam, Jose A.
    Kassouf, Wassim
    Mitchell, Thomas
    Montironi, Rodolfo
    O'Brien, Tim
    Panebianco, Valeria
    Scelo, Ghislaine
    Shuch, Brian
    van Poppel, Hein
    Blosser, Christopher D.
    Psutka, Sarah P.
    [J]. EUROPEAN UROLOGY, 2022, 82 (05) : 529 - 542
  • [15] Tertiary lymphoid structures improve immunotherapy and survival in melanoma
    Cabrita, Rita
    Lauss, Martin
    Sanna, Adriana
    Donia, Marco
    Larsen, Mathilde Skaarup
    Mitra, Shamik
    Johansson, Iva
    Phung, Bengt
    Harbst, Katja
    Vallon-Christersson, Johan
    van Schoiack, Alison
    Loevgren, Kristina
    Warren, Sarah
    Jirstroem, Karin
    Olsson, Hakan
    Pietras, Kristian
    Ingvar, Christian
    Isaksson, Karolin
    Schadendorf, Dirk
    Schmidt, Henrik
    Bastholt, Lars
    Carneiro, Ana
    Wargo, Jennifer A.
    Svane, Inge Marie
    Jonsson, Goran
    [J]. NATURE, 2020, 577 (7791) : 561 - +
  • [16] Rheumatic immune-related adverse events from cancer immunotherapy
    Calabrese, Leonard H.
    Calabrese, Cassandra
    Cappelli, Laura C.
    [J]. NATURE REVIEWS RHEUMATOLOGY, 2018, 14 (10) : 569 - 579
  • [17] Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma
    Calderaro, Julien
    Petitprez, Florent
    Becht, Etienne
    Laurent, Alexis
    Hirsch, Theo Z.
    Rousseau, Benoit
    Luciani, Alain
    Amaddeo, Giuliana
    Derman, Jonathan
    Charpy, Cecile
    Zucman-Rossi, Jessica
    Fridman, Wolf Herman
    Sautes-Fridman, Catherine
    [J]. JOURNAL OF HEPATOLOGY, 2019, 70 (01) : 58 - 65
  • [18] Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma
    Castino, Giovanni Francesco
    Cortese, Nina
    Capretti, Giovanni
    Serio, Simone
    Di Caro, Giuseppe
    Mineri, Rossana
    Magrini, Elena
    Grizzi, Fabio
    Cappello, Paola
    Novelli, Francesco
    Spaggiari, Paola
    Roncalli, Massimo
    Ridolfi, Cristina
    Gavazzi, Francesca
    Zerbi, Alessandro
    Allavena, Paola
    Marchesi, Federica
    [J]. ONCOIMMUNOLOGY, 2016, 5 (04):
  • [19] STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment
    Chelvanambi, Manoj
    Fecek, Ronald J.
    Taylor, Jennifer L.
    Storkus, Walter J.
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (02)
  • [20] Cancer Statistics in China, 2015
    Chen, Wanqing
    Zheng, Rongshou
    Baade, Peter D.
    Zhang, Siwei
    Zeng, Hongmei
    Bray, Freddie
    Jemal, Ahmedin
    Yu, Xue Qin
    He, Jie
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2016, 66 (02) : 115 - 132